Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
出版年份 2014 全文链接
标题
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
作者
关键词
Melanoma, Overall Survival, Ipilimumab, Vemurafenib, Chimeric Antigen Receptor
出版物
Journal of Translational Medicine
Volume 12, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-10-28
DOI
10.1186/s12967-014-0277-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma
- (2014) B. Schilling et al. ANNALS OF ONCOLOGY
- Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients
- (2014) Charles M. Balch et al. ANNALS OF SURGICAL ONCOLOGY
- Inducible Nitric Oxide Synthase Drives mTOR Pathway Activation and Proliferation of Human Melanoma by Reversible Nitrosylation of TSC2
- (2014) E. Lopez-Rivera et al. CANCER RESEARCH
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
- (2014) T. Chodon et al. CLINICAL CANCER RESEARCH
- Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma
- (2014) Guo Chen et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Melanoma NOS1 expression promotes dysfunctional IFN signaling
- (2014) Qiuzhen Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable Disease
- (2014) Shanthi Sivendran et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
- (2014) Amanda Lassen et al. Molecular Cancer
- A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
- (2014) J. Xia et al. MOLECULAR CANCER THERAPEUTICS
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
- (2014) Dennie T. Frederick et al. PLoS One
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
- (2013) J. D. Wolchok et al. ANNALS OF ONCOLOGY
- Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases
- (2013) Charles M. Balch et al. ANNALS OF SURGICAL ONCOLOGY
- Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
- (2013) Corrado Caracò et al. BMC CANCER
- That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance
- (2013) Matthew J Sale et al. BRITISH JOURNAL OF PHARMACOLOGY
- Melanoma Genetic Counseling and Test Reporting Improve Screening Adherence Among Unaffected Carriers 2 Years Later
- (2013) L. G. Aspinwall et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
- (2013) S. Mok et al. CANCER RESEARCH
- Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
- (2013) A. Morales-Kastresana et al. CLINICAL CANCER RESEARCH
- Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
- (2013) M. J. Besser et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Combining cancer immunotherapy and targeted therapy
- (2013) Antoni Ribas et al. CURRENT OPINION IN IMMUNOLOGY
- Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
- (2013) Bastian Schilling et al. INTERNATIONAL JOURNAL OF CANCER
- Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A
- (2013) D. Hammond et al. JOURNAL OF CELL SCIENCE
- T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes
- (2013) I. Martinez-Forero et al. JOURNAL OF IMMUNOLOGY
- The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
- (2013) K. Mimura et al. JOURNAL OF IMMUNOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAC1P29S is a spontaneously activating cancer-associated GTPase
- (2013) M. J. Davis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
- (2012) B Weide et al. BRITISH JOURNAL OF CANCER
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
- (2012) Victoria Del Gaizo Moore et al. CANCER LETTERS
- The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
- (2012) D. Wroblewski et al. CARCINOGENESIS
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
- (2012) K. H. T. Paraiso et al. CLINICAL CANCER RESEARCH
- BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma
- (2012) Travis B. Kidner et al. JOURNAL OF IMMUNOTHERAPY
- IRF5 gene polymorphisms in melanoma
- (2012) Lorenzo Uccellini et al. Journal of Translational Medicine
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
- (2012) Amélie Clémentine Seghers et al. MELANOMA RESEARCH
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- (2012) Michael Krauthammer et al. NATURE GENETICS
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
- (2012) Daniela Senft et al. PLoS One
- The role of classical and non-classical HLA class I antigens in human tumors
- (2012) Juergen Bukur et al. SEMINARS IN CANCER BIOLOGY
- The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
- (2012) Asís Palazón et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Association of IFN- Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines
- (2011) A. Respa et al. CLINICAL CANCER RESEARCH
- A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
- (2011) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database
- (2011) John F. Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
- (2011) Yuan Yuan et al. Journal of Hematology & Oncology
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma
- (2011) Jeffrey E. Gershenwald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- 2010 TNM Staging System for Cutaneous Melanoma…and Beyond
- (2010) Jeffrey E. Gershenwald et al. ANNALS OF SURGICAL ONCOLOGY
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- CSPG4 in Cancer: Multiple Roles
- (2010) X. Wang et al. CURRENT MOLECULAR MEDICINE
- Identification of E2F1 as an Important Transcription Factor for the Regulation of Tapasin Expression
- (2010) Juergen Bukur et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
- (2010) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell therapy for the treatment of patients with metastatic melanoma
- (2009) Steven A Rosenberg et al. CURRENT OPINION IN IMMUNOLOGY
- A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
- (2009) Karl D. Lewis et al. INVESTIGATIONAL NEW DRUGS
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling
- (2009) Lisa G. Aspinwall et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue
- (2009) Stephen S Koh et al. MODERN PATHOLOGY
- Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival
- (2009) D. Bogunovic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognosis and Determinants of Outcome Following Locoregional or Distant Recurrence in Patients with Cutaneous Melanoma
- (2008) Anne Brecht Francken et al. ANNALS OF SURGICAL ONCOLOGY
- Loss of interferon-γ inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation
- (2008) M. Meissner et al. BRITISH JOURNAL OF DERMATOLOGY
- CDKN2A/p16 Genetic Test Reporting Improves Early Detection Intentions and Practices in High-Risk Melanoma Families
- (2008) L. G. Aspinwall et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Digital mRNA profiling
- (2008) Paolo Fortina et al. NATURE BIOTECHNOLOGY
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started